Harvest One Subsidiary Satipharm Granted US Patent Covering Gelpell(TM) Technology

Vancouver, British Columbia--(Newsfile Corp. - November 12, 2020) - Harvest One Cannabis Inc. (TSXV: HVT) (OTCQX: HRVOF) ("Harvest One" or the "Company") announced today that the United States Patent and Trademark Office has granted its wholly-owned subsidiary Satipharm Ltd. ("Satipharm") US Pat No. 10,555,906 covering Satipharm's proprietary Gelpell^™ technology.

This issued patent, titled "Oral solid cannabinoid formulations, methods for producing and use thereof", protects Satipharm's licenced Gelpell^™ technology in the United States with respect to diverse cannabinoid formulations, including pure CBD products and combinations of cannabinoids such as full spectrum products. The patent covers compositions including oral solid dosage forms and also covers therapeutic applications for the treatment of various disorders and conditions.

The need for effective oral delivery of cannabinoids is essential for the development of stable and predictable therapeutic treatments. The patented compositions feature the high bioavailability of the Gelpell^™ technology, as well as prolonged stability at room temperature, two critical factors in achieving predictable treatments.

"Receipt of this patent represents an important milestone for Satipharm, completing the patenting process for key jurisdictions," said Gord Davey, President and Interim Chief Executive Officer of Harvest One. "This patent, combined with our published Phase I and II clinical trials, further emphasizes the strength of the Satipharm brand as we pursue commercial partners for various pharmaceutical, nutraceutical and recreational applications. The issuance of this patent comes at an important time following the recent US election and the anticipated federal legalization of cannabinoids in the US."

The Company has obtained patents covering Gelpell^™ technology in the key markets, including the United States, Canada, United Kingdom, Australia and countries of the European Union.

Satipharm products are currently on sale in major pharmacy chains and retailers throughout the United Kingdom and Ireland, including Boots, Lloyds and Holland & Barret. Satipharm's suite of products includes their flagship 'Advanced' capsule range, powered by Gelpell^™ technology, consisting of the original 10mg CBD capsule, the Focus and Active co-formulation variants, the high strength 50mg CBD capsule, plus a range of CBD oils providing a differentiated market offering to satisfy a large consumer base.

Satipharm Gelpell^™ Capsules

Satipharm produces CBD capsules powered by proprietary Gelpell^™ technology. These capsules take a different approach to other cannabinoid products currently on the market. Gelpell™ capsules embed the full spectrum hemp extract CBD in seamless gelatine microspheres. These tiny beads have been clinically proven to increase the bioavailability of CBD, maximising the delivery of CBD to the body. Manufactured in Switzerland and GMP certified, every Gelpell^™ capsule delivers a consistent dose of cannabinoids.

Satipharm CBD Gelpell capsules have 3.5 times higher bioavailability compared to standard CBD oils. This unique product has undergone both Phase I and II clinical trials with the results published in two peer-reviewed international medical journals.

For further details on the clinical trials, please visit our website;
https://www.harvestone.com/portfolio/satipharm/#clinical-trials.

About Harvest One

Harvest One is a global company that develops and distributes premium health, wellness and selfcare products with a market focus on sleep, pain, and anxiety. Harvest One is a uniquely positioned company in the cannabis space with a focus on cannabis infused and non-infused consumer packaged goods. Harvest One owns and operates three subsidiaries; Dream Water Global, LivReief (consumer) and Satipharm (medical and nutraceutical). For more information, please visit www.harvestone.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. The forward-looking information contained in this press release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.

Investor Relations:
Colin Clancy
Investor Relations
[email protected]
1-877-915-7934

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/68033